Moderate

IgG4-related disease (IgG4-RD; autoimmune pancreatitis, Mikulicz, retroperitoneal fibrosis)

IgG4-related disease · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Immune-mediated fibroinflammatory condition that forms tumefactive (mass-like) lesions in virtually any organ, with characteristic histology (dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis) and often (not always) raised serum IgG4. Common presentations: type 1 autoimmune pancreatitis, sclerosing cholangitis, bilateral salivary/lacrimal gland swelling (Mikulicz), orbital pseudotumour, retroperitoneal fibrosis, tubulointerstitial nephritis, aortitis. Typically older men. Frequently mistaken for malignancy or infection; highly glucocorticoid-responsive but relapses are common.

Figures & algorithms

Atlanta classification
Atlanta classification

Red flags

  • Obstructive jaundice / cholangitis — biliary involvement needs urgent decompression (and rule out cholangiocarcinoma)
  • Back/abdominal pain with hydronephrosis — retroperitoneal fibrosis causing ureteric obstruction/AKI
  • Chest/back pain, aneurysm — IgG4 aortitis/periaortitis (dissection/rupture risk)
  • Mass lesion mimicking cancer — never immunosuppress without excluding malignancy
  • Rapidly declining organ function — organ-threatening disease needs prompt steroids

Assessment

Differential diagnosis

  • Malignancy (pancreatic/cholangiocarcinoma, lymphoma, orbital/salivary tumour) — must exclude with biopsy
  • Sjogren syndrome (anti-Ro/La positive; IgG4-RD anti-Ro negative)
  • Sarcoidosis, granulomatosis with polyangiitis
  • Primary sclerosing cholangitis
  • Idiopathic retroperitoneal fibrosis, Erdheim-Chester, histiocytoses

Investigations

  • Serum IgG4 + total IgG/IgG subclasses (raised IgG4 supportive but ~30% normal; high levels can be malignancy/infection too)
  • Biopsy of affected organ — diagnostic gold standard (storiform fibrosis, IgG4+/IgG+ plasma cell ratio, obliterative phlebitis)
  • Cross-sectional imaging (CT/MRI) of involved organs; 'sausage' pancreas, periaortitis, renal cortical lesions
  • PET-CT to map multi-organ involvement and guide biopsy
  • Complement C3/C4 (low in active renal disease), eosinophils/IgE (often raised)
  • Organ function: LFTs, amylase/lipase, U&E, urinalysis depending on site; exclude malignancy first

Management

  • Establish diagnosis histologically where feasible and EXCLUDE malignancy/infection before immunosuppression
  • Assess extent (PET-CT) and identify organ-threatening involvement (biliary obstruction, aortitis, renal, pancreatic)
  • Induce remission with glucocorticoids — prednisolone ~0.6 mg/kg/day for 2-4 weeks then taper over 3-6 months (dramatic response typical)
  • Use rituximab for relapsing, steroid-refractory, steroid-dependent disease or where steroids contraindicated (e.g. diabetes)
  • Steroid-sparing agents (azathioprine, mycophenolate, methotrexate) sometimes added for maintenance
  • Relieve mechanical obstruction (biliary stent for cholangitis, ureteric stent for retroperitoneal fibrosis) as needed
  • Monitor for relapse clinically, biochemically (IgG4) and with imaging; attempt to stop steroids within ~3 years given elderly/comorbid population
  • Screen and manage steroid complications (glucose, bone, infection)

Drugs & doses

Prednisolone 0.6 mg/kg/day (commonly ~30-40 mg) ORALLY for 2-4 weeks, then taper over 3-6 months [verify local dose]
Rituximab 1 g IV x2 (2 weeks apart) for relapsing/refractory/steroid-sparing or steroid-contraindicated disease [verify local]
Steroid-sparing maintenance: azathioprine 2 mg/kg/day, mycophenolate mofetil 1-1.5 g twice daily, or methotrexate weekly [verify local]
Bone/gastric protection + glucose monitoring during steroid course (bisphosphonate/calcium-vitamin D, PPI) [verify local]
Pneumocystis prophylaxis (co-trimoxazole) if prolonged high-dose immunosuppression [verify local]

Disposition

Outpatient rheumatology/organ-specialist MDT. Admit/urgent referral for obstructive jaundice, ureteric obstruction with AKI, or aortic complication.

Complications & pitfalls

  • Organ fibrosis and failure (pancreatic insufficiency, biliary cirrhosis, CKD)
  • Ureteric obstruction/hydronephrosis from retroperitoneal fibrosis
  • Aortic aneurysm/dissection
  • Relapse (common) and steroid-related morbidity
  • Diagnostic delay / misdiagnosis as malignancy

Exam pearls

  • Always exclude malignancy and infection first — IgG4-RD forms tumefactive masses that mimic cancer; biopsy is gold standard.
  • Serum IgG4 is supportive, not diagnostic — ~30% have normal levels and high levels occur in other conditions.
  • Response to glucocorticoids is typically dramatic and is almost part of the diagnosis; relapse on tapering is common.
  • Rituximab is the key agent for relapsing/steroid-dependent disease or when steroids are contraindicated (e.g. diabetes).
  • Attempt to withdraw steroids within ~3 years — the population is elderly and steroid-vulnerable.
  • Think IgG4-RD in retroperitoneal fibrosis, autoimmune pancreatitis, orbital pseudotumour and tubulointerstitial nephritis.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.